Protagenic Therapeutics (OTCMKTS:PTIX) Lifted to “Buy” at ValuEngine

ValuEngine upgraded shares of Protagenic Therapeutics (OTCMKTS:PTIX) from a hold rating to a buy rating in a report issued on Tuesday, ValuEngine reports.

PTIX opened at $1.50 on Tuesday. Protagenic Therapeutics has a 12 month low of $1.25 and a 12 month high of $2.50. The stock has a 50-day moving average of $1.50.

Protagenic Therapeutics (OTCMKTS:PTIX) last announced its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder.

Read More: What is the Coverage Ratio?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.